Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome
- 1 November 2001
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 95 (6) , 668-672
- https://doi.org/10.1016/s0035-9203(01)90110-5
Abstract
We evaluated generic sodium stibogluconate (SSG) (International Dispensary Association, Amsterdam) versus Pentostam® (sodium stibogluconate, GlaxoWelKeywords
This publication has 7 references indexed in Scilit:
- A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in SudanTropical Medicine & International Health, 2000
- High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.The American Journal of Tropical Medicine and Hygiene, 1999
- Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin BAIDS, 1999
- Infection of sand flies by humans coinfected with Leishmania infantum and human immunodeficiency virus.The American Journal of Tropical Medicine and Hygiene, 1999
- In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasisAntimicrobial Agents and Chemotherapy, 1997
- Epidemic Visceral Leishmaniasis in Southern Sudan: Treatment of Severely Debilitated Patients under Wartime Conditions and with Limited ResourcesAnnals of Internal Medicine, 1996
- Epidemic Visceral Leishmaniasis in Sudan: A Randomized Trial of Aminosidine plus Sodium Stibogluconate versus Sodium Stibogluconate AloneThe Journal of Infectious Diseases, 1993